HomeFileStructural heart disease

Structural heart disease

Melody: One of the Pioneers in Transcatheter Pulmonary Valve Replacement with Long Term Outcomes

At 10 years of the Melody Investigational Device Exemption we can observe this device for transcatheter pulmonary...

HYDRA CE | New Models for TAVR Development

The Hydra CE has shown favorable one year efficacy for the new transcatheter aortic valve model, with...

Left Atrial Appendage Closure vs Direct Anticoagulants at Long Term

The PRAGUE-17 has shown that left atrial appendage closure is not inferior to direct anticoagulants at long...

Minimizing One of Our Major Procedures to a Minimum

In some cases, full atrioventricular (AV) block occurs beyond two days after transcatheter aortic valve replacement (TAVR)....

The FDA Approves Sapien 3 with Alterra in Pulmonary Position

The US Food and Drug Administration (FDA) has cleared the SAPIEN 3 valve with the Alterra adaptive pre-stent...

The Most Relevant of 2021 In Structural Heart Disease

This last year, new data in structural heart disease gave way to changes in practices and new...

The Most Read Articles of 2021: Structural Heart Disease

A new year is coming to an end and at SOLACI we are going over the most...

PRAGUE-17: Appendage Closure vs. Direct Anticoagulant Agents

After four years of follow-up, the PRAGUE-17 study showed that appendage closure is non-inferior to direct anticoagulant...